Recent research into the influence of human anti-LMP1 IgG antibody (LMP1-IgG) on the JAK/STAT signalling pathway on extranodal nasal-type natural killer (NK)/T cell lymphoma showed LMP1-IgG significantly inhibited the phosphorylation of STAT3 and JAK3, suggesting a potential therapeutic impact of targeting the JAK/STAT pathway [172]. This evidence concerns the gene PDLIM7 and T-cell non-Hodgkin lymphoma.